Patents by Inventor Karl Guegler
Karl Guegler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240218466Abstract: A stand-alone molecular diagnostic test device includes a housing, a reverse transcription module, an amplification module, and a detection module. The reverse transcription module is configured to heat a biological sample to produce a target cDNA molecule associated with an RNA virus thereby producing an amplification solution. The amplification module defines a reaction volume configured to receive the amplification solution and amplify the target cDNA molecule within the amplification solution to produce an output. The detection module is configured to receive the output from the amplification module and includes one or more probes specific to a polynucleotide sequence of the RNA virus. The one or more probes is designed to facilitate production of a signal indicating the presence of the RNA virus in the biological sample.Type: ApplicationFiled: March 23, 2021Publication date: July 4, 2024Inventors: Mackenzie HUNT, Karl GUEGLER, David SWENSON, Shaunak ROY, Paul DENTINGER, Brian CIOPYK, Samira DASWANI, Gary SCHOOLNIK, Teresa ABRAHAM
-
Patent number: 11952636Abstract: The disclosure relates generally to molecular diagnostic devices configured to amplifying a single nucleotide polymorphism (SNP) locus and discriminate between two or more allelic variants of the SNP, indicating presence or absence of a target allele. In some embodiments, the molecular diagnostic devices are capable of detecting, at point-of-care, SNPs associated with resistance or susceptibility to antibiotic treatment of organism infections. In other aspects, the disclosure provides methods of treatment for disease or disorders (e.g. organism infections) where treatment is guided by presence or absence of an allele at a SNP locus as determined by such molecular diagnostic devices.Type: GrantFiled: May 6, 2022Date of Patent: April 9, 2024Assignee: Visby Medical, Inc.Inventors: Brian Ciopyk, Paul Dentinger, Teresa Abraham, Brandon Ma, Kamal Kajouke, Mackenzie Hunt, Austin Phung, Karl Guegler, David Swenson, Anna H. Postlethwaite
-
Publication number: 20220112550Abstract: The invention is directed to methods for analyzing polymers comprising linear chains of at least two types of monomers, such as polynucleotides, including DNA, RNA, and the like, using nanopores and optical detection. In some embodiments, as few as two different kinds of nucleotide are labeled with different optical labels that generate distinguishable optical signals for the selected kinds of nucleotide in both sense strands and antisense strands of target polynucleotides. Labeled strands are translocated through nanopores where nucleotides of the strands are constrained to pass sequentially through an optical detection region where their labels generate a sequence of optical signals making up an optical signature. In some embodiments, information from optical signatures from both sense and antisense strands are combined to determine complete nucleotide sequences of target polynucleotides.Type: ApplicationFiled: August 3, 2021Publication date: April 14, 2022Applicant: Quantapore, Inc.Inventors: Karl GUEGLER, Jan F. SIMONS, Stephen C. MACEVICZ
-
Publication number: 20220106629Abstract: The invention provides methods for analyzing polynucleotides using nanopores that allow passage of single stranded polynucleotides but not double stranded polynucleotides. In accordance with some embodiments, a double-stranded product is produced that comprises a labeled strand with a single stranded tail or overhang. The double stranded product is exposed to one or more nanopores in the presence of an electric field across the one or more nanopores such that the single stranded tail may be captured and the labeled strand translocated by unzipping from the double stranded product. The ionic composition of the reaction mixture and electric field strength are selected so that nucleotides translocate a nanopore at a rate of less than 1000 nucleotides per second.Type: ApplicationFiled: July 2, 2021Publication date: April 7, 2022Applicant: Quantapore, Inc.Inventors: Tao HONG, Karl GUEGLER, Jan F. SIMONS
-
Publication number: 20190112649Abstract: The invention is directed to methods for analyzing polymers comprising linear chains of at least two types of monomers, such as polynucleotides, including DNA, RNA, and the like, using nanopores and optical detection. In some embodiments, as few as two different kinds of nucleotide are labeled with different optical labels that generate distinguishable optical signals for the selected kinds of nucleotide in both sense strands and antisense strands of target polynucleotides. Labeled strands are translocated through nanopores where nucleotides of the strands are constrained to pass sequentially through an optical detection region where their labels generate a sequence of optical signals making up an optical signature. In some embodiments, information from optical signatures from both sense and antisense strands are combined to determine complete nucleotide sequences of target polynucleotides.Type: ApplicationFiled: May 4, 2017Publication date: April 18, 2019Applicant: Quantapore, Inc.Inventors: Karl GUEGLER, Jan F. SIMONS, Stephen C. MACEVICZ
-
Publication number: 20190078145Abstract: The invention provides methods for analyzing polynucleotides using nanopores that allow passage of single stranded polynucleotides but not double stranded polynucleotides. In accordance with some embodiments, a double-stranded product is produced that comprises a labeled strand with a single stranded tail or overhang. The double stranded product is exposed to one or more nanopores in the presence of an electric field across the one or more nanopores such that the single stranded tail may be captured and the labeled strand translocated by unzipping from the double stranded product. The ionic composition of the reaction mixture and electric field strength are selected so that nucleotides translocate a nanopore at a rate of less than 1000 nucleotides per second.Type: ApplicationFiled: November 28, 2016Publication date: March 14, 2019Applicant: QUANTAPORE, INC.Inventors: Tao HONG, Karl GUEGLER, Jan F. SIMONS
-
Publication number: 20180237843Abstract: Disclosed are methods and compositions for determining the average length or abundance of a first target nucleic by calculating the abundance of a first target nucleic acid (T) relative to the average abundance (S) of a second and a third target nucleic acid, in a single well using a separate detection label for each target nucleic acid. In various aspects, the first target nucleic acid is a telomere. In exemplary aspects, the disclosed methods and compositions can be used to determine the average telomere length in a biological sample. The average telomere length determined using the disclosed methods and compositions can be correlated to a variety of clinically important conditions and indices. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: April 16, 2018Publication date: August 23, 2018Inventors: Calvin Harley, Jue Lin, Karl Guegler
-
Patent number: 9944978Abstract: Disclosed are methods and compositions for determining the average length or abundance of a first target nucleic by calculating the abundance of a first target nucleic acid (T) relative to the average abundance (S) of a second and a third target nucleic acid, in a single well using a separate detection label for each target nucleic acid. In various aspects, the first target nucleic acid is a telomere. In exemplary aspects, the disclosed methods and compositions can be used to determine the average telomere length in a biological sample. The average telomere length determined using the disclosed methods and compositions can be correlated to a variety of clinically important conditions and indices. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: June 22, 2015Date of Patent: April 17, 2018Assignee: TELOMERE DIAGNOSTICS, INC.Inventors: Calvin Harley, Jue Lin, Karl Guegler
-
Publication number: 20170233791Abstract: Provided herein are methods and compositions for performing PCR with primers with blocked 3?-ends that are unblocked when these primers anneal to the template. The multiplexed PCR can be used as real-time qPCR, for end-point detection or as enrichment method for next generation sequencing (NGS). Also described herein are methods and compositions to improve sensitivity of mutation-specific PCR when targeting closely-spaced mutations.Type: ApplicationFiled: December 19, 2016Publication date: August 17, 2017Inventors: Eugene Spier, Karl Guegler
-
Patent number: 9523121Abstract: Provided herein are methods and compositions for performing PCR with primers with blocked 3?-ends that are unblocked when these primers anneal to the template. The multiplexed PCR can be used as real-time qPCR, for end-point detection or as enrichment method for next generation sequencing (NGS). Also described herein are methods and compositions to improve sensitivity of mutation-specific PCR when targeting closely-spaced mutations.Type: GrantFiled: January 13, 2014Date of Patent: December 20, 2016Assignee: Uni Taq BioInventors: Eugene Spier, Karl Guegler
-
Patent number: 9518296Abstract: The present teachings provide methods, compositions, and kits for detecting the presence of protein aggregates. In some embodiments, the protein aggregate is treated with a labeled precursor, and the labeled precursor is incorporated into the protein aggregate to form a labeled protein aggregate. The labeled protein aggregate is then measured, thus detecting the presence of the protein aggregate. In some embodiments, the labeled protein aggregate is detected by interaction of labeled precursors, for example by a proximity ligation assay.Type: GrantFiled: August 23, 2013Date of Patent: December 13, 2016Assignee: APPLIED BIOSYSTEMS LLCInventors: David Ruff, Mark Shannon, Kenneth Livak, Karl Guegler, Kevin Hennessy
-
Publication number: 20160186250Abstract: Disclosed are methods and compositions for determining the average length or abundance of a first target nucleic by calculating the abundance of a first target nucleic acid (T) relative to the average abundance (S) of a second and a third target nucleic acid, in a single well using a separate detection label for each target nucleic acid. In various aspects, the first target nucleic acid is a telomere. In exemplary aspects, the disclosed methods and compositions can be used to determine the average telomere length in a biological sample. The average telomere length determined using the disclosed methods and compositions can be correlated to a variety of clinically important conditions and indices. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: June 22, 2015Publication date: June 30, 2016Inventors: Calvin Harley, Jue Lin, Karl Guegler
-
Publication number: 20140329245Abstract: Provided herein are methods and compositions for performing PCR with primers with blocked 3?-ends that are unblocked when these primers anneal to the template. The multiplexed PCR can be used as real-time qPCR, for end-point detection or as enrichment method for next generation sequencing (NGS). Also described herein are methods and compositions to improve sensitivity of mutation-specific PCR when targeting closely-spaced mutations.Type: ApplicationFiled: January 13, 2014Publication date: November 6, 2014Applicant: UniTaq BioInventors: Eugene Spier, Karl Guegler
-
Publication number: 20140134624Abstract: The present teachings provide methods, compositions, and kits for detecting the presence of protein aggregates. In some embodiments, the protein aggregate is treated with a labeled precursor, and the labeled precursor is incorporated into the protein aggregate to form a labeled protein aggregate. The labeled protein aggregate is then measured, thus detecting the presence of the protein aggregate. In some embodiments, the labeled protein aggregate is detected by interaction of labeled precursors, for example by a proximity ligation assay.Type: ApplicationFiled: August 23, 2013Publication date: May 15, 2014Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: David RUFF, Mark Shannon, Kenneth Livak, Karl Guegler, Kevin Hennessy
-
Publication number: 20080003604Abstract: The present teachings provide methods, compositions, and kits for detecting the presence of protein aggregates. In some embodiments, the protein aggregate is treated with a labeled precursor, and the labeled precursor is incorporated into the protein aggregate to form a labeled protein aggregate. The labeled protein aggregate is then measured, thus detecting the presence of the protein aggregate. In some embodiments, the labeled protein aggregate is detected by interaction of labeled precursors, for example by a proximity ligation assay.Type: ApplicationFiled: May 2, 2007Publication date: January 3, 2008Applicant: Applera CorporationInventors: David Ruff, Mark Shannon, Kenneth Livak, Karl Guegler, Kevin Hennessy
-
Publication number: 20070111226Abstract: The present teachings provide methods, compositions, and kits for quantifying target polynucleotides. In some embodiments, a reverse stem-loop ligation probe is ligated to the 3? end of a target polynucleotide, using a ligase that can ligate the 3? end of RNA to the 5? end of DNA using a DNA template, such as T4 DNA ligase. Following digestion to form an elongated target polynucleotide with a liberated end, a reverse transcription reaction can be performed, followed by a PCR. In some embodiments, the methods of the present teachings can discriminate between polymorphic polynucleoitides that vary by as little as one nucleotide.Type: ApplicationFiled: August 24, 2006Publication date: May 17, 2007Applicant: APPLERA CORPORATIONInventors: Ruoying Tan, Caifu Chen, Karl Guegler
-
Publication number: 20070105171Abstract: The invention provides human protease molecules (HUPM) and polynucleotides which identify and encode HUPM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HUPM.Type: ApplicationFiled: October 2, 2006Publication date: May 10, 2007Applicants: Incyte Pharmaceuticals, Inc., Genentech, Inc.Inventors: Olga Bandman, Jennifer Hillman, Henry Yue, Karl Guegler, Neil Corley, Y. Tang, Purvi Shah
-
Publication number: 20070054312Abstract: The invention provides human transmembrane proteins (HTMPN) and polynucleotides which identify and encode HTMPN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HTMPN.Type: ApplicationFiled: November 8, 2006Publication date: March 8, 2007Inventors: Y. Tang, Preeti Lal, Jennifer Hillman, Henry Yue, Karl Guegler, Neil Corley, Olga Bandman, Chandra Patterson, Gina Gorgone, Matthew Kaser, Mariah Baughn, Janice Au-Young
-
Publication number: 20060281902Abstract: The invention provides a human signal peptide-containing proteins (SIGP) and polynucleotides which identify and encode SIGP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of SIGP.Type: ApplicationFiled: March 23, 2006Publication date: December 14, 2006Inventors: Preeti Lal, Jennifer Hillman, Neil Corley, Karl Guegler, Mariah Baughn, Susan Sather, Purvi Shah
-
Publication number: 20060246486Abstract: The invention provides a human signal peptide-containing proteins (SIGP) and polynucleotides which identify and encode SIGP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of SIGP.Type: ApplicationFiled: March 23, 2006Publication date: November 2, 2006Inventors: Preeti Lal, Jennifer Hillman, Neil Corley, Karl Guegler, Mariah Baughn, Susan Sather, Purvi Shah